

PERSONAL INFORMATION Adalgisa Condoluci



DOB: 19 Oct 1989

Place of birth: Taurianova (RC, Italy)

Nationality and Mother Tongue: Italian

Other languages: English (fluent), French (fluent), German (basic), Spanish (basic)

Address: Via Tommaso Rodari, 13 - 6500 Bellinzona (Switzerland)

T: (+41) 076.221.19.89

Email: adalgisa.condoluci@gmail.com

Personal qualities: Drive and determination; Teamwork; Leadership; Problem-solving; Flexibility

Artistic skills: Pianist; Alto singer

POSITION Resident Physician in Hematology MD-PhD Student in Cancer Biology and Oncology

EDUCATION AND TRAINING

08/2021–Present	MD-PhD track Università della Svizzera Italiana, Lugano (Switzerland) – PhD in Cancer Biology and Oncology, Institute of Oncology Research, Bellinzona (Switzerland)
10/2021	FMH Hematology Exam
06/2021	European Hematology Exam European Hematology Association
04/2021	Introductory Course in Laboratory Animal Science University of Zürich – LTK M1 (species Rats and Mice), FELASA n: LTK5440
05/2019 – 11/2020	Certificate of Advanced Studies in Lymphoma European School of Oncology – University of Ulm, 14 ECTS
06/2020	Swiss Board Examination in General Internal Medicine SGAIM SSMIG SSGIM – Switzerland
02/2019 – 11/2019	Young Oncology Academy Swiss Group for Clinical Cancer Research – SAKK, Bern
10/2008–07/2014	Degree in Medicine and Surgery University Campus Bio-Medico di Roma, Roma (Italy), Cum laude ERASMUS Program - Université de Lyon 1, Lyon (France)
09/2009	Piano degree Conservatory of Music “F. Cilea”, Reggio Calabria (Italy), Maxima cum laude

WORK EXPERIENCE

07/2015–Present	Resident Physician EOC - ORBV, Bellinzona (Switzerland) <ul style="list-style-type: none">09/2021 – Present: Clinic of Hematology, Oncology Institute of Southern Switzerland09/2019 – 08/2021: Department of Internal Medicine07/2016 – 08/2019: Clinic of Hematology, Oncology Institute of Southern Switzerland07/2015 – 06/2016: Department of Thoracic Surgery
01/2017–07/2021	Attendant Physician Institute of Oncology Research, Bellinzona (Switzerland) Translational research: Lymphoproliferative diseases, Cell-free DNA, Mutational analysis, Statistical analysis, Data management

TEACHING ACTIVITY

2021-2022 Università della Svizzera Italiana, Lugano, Switzerland
Master of Medicine lectures, Bedside Teaching, OSCE Exam Officer

SCIENTIFIC ACTIVITY

Academic age: 8; Academic age (hematology): 6

Research topics of interest

Translational research, Lymphoproliferative diseases, B cell malignancies, Cancer genetics, Cancer microenvironment, Prognostication

List of publications

- 1) **Condoluci A**, Milan L, Forestieri G, Terzi di Bergamo L, Spina V, Bruscazzin A, Deambrogi C, Moia R, Deodato M, Fahmi G, Mattarucchi R, Merli M, Gerber B, Stussi G, Passamonti F, Gregor M, Tedeschi A, Gaidano G, Rossi D, Ceriani L. Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib. *Hematol Oncol.* 2022
- 2) Forestieri G, Terzi di Bergamo L, Deodato M, Frustaci AM, Moia R, Deambrogi C, Rasi S, Autore F, Merli M, Mattarucchi R, Fahmi G, Scarfo L, Gussetti D, Bulian P, Zanatta A, Spina V, Bruscazzin A, Pini K, Piffaretti D, Piroso MC, Salehi M, Marques de Almeida J, Passweg J, Cavalli F, Zucca E, Gerber B, Stussi G, Gattei V, Ghia P, Gregor M, Passamonti F, Laurenti L, Gaidano G, Tedeschi A, Rossi D, **Condoluci A**. Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia. *Hematol Oncol.* 2022
- 3) **Condoluci A**, Rossi D. Biology and Treatment of Richter Transformation. *Front Oncol.* 2022
- 4) Bonfiglio F, Bruscazzin A, Guidetti F, Terzi di Bergamo L, Faderl M, Spina V, **Condoluci A**, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Piroso MC, Cittone MG, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista MJ, Bastidas G, Bea S, Boldorini R, Broccoli A, Buehler MM, Canzonieri V, Cascione L, Ceriani L, Cogliatti S, Corradini P, Derenzini E, Devizzi L, Dietrich S, Elia AR, Facchetti F, Gaidano G, Garcia JF, Gerber B, Ghia P, Gomes da Silva M, Gritti G, Guidetti A, Hitz F, Inghirami G, Ladetto M, Lopez-Guillermo A, Lucchini E, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia A, Mollejo M, Montalban C, Novak U, Oscier DG, Passamonti F, Piazza F, Pizzolitto S, Rambaldi A, Sabattini E, Salles G, Santambrogio E, Scarfo L, Stathis A, Stüssi G, Geyer JT, Tapia G, Tarella C, Thieblemont C, Tousseyn T, Tucci A, Vanini G, Visco C, Vitolo U, Walewska R, Zaja F, Zenz T, Zinzani PL, Khiabani H, Calcinotto A, Bertoni F, Bhagat G, Campo E, De Leval L, Dirnhofer S, Pileri SA, Piris MA, Traverse-Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F, Zucca E, Rossi D. Genetic and phenotypic attributes of splenic marginal zone lymphoma. *Blood.* 2022
- 5) Bruscazzin A, di Bergamo LT, Spina V, Hodgkinson B, Forestieri G, Bonfiglio F, **Condoluci A**, Wu W, Piroso MC, Faderl MR, Koch R, Schaffer M, Alvarez JD, Fournieu N, Gerber B, Stussi G, Zucca E, Balasubramanian S, Rossi D. Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab. *Blood Adv.* 2021
- 6) **Condoluci A**, Théaudin M, Schwotzer R, Pazhenkottil AP, Arosio P, Averaimo M, Bacher U, Bode P, Cavalli A, Dirnhofer S, Djerbi N, Dobner S, Fehr T, Garofalo M, Gaspert A, Gerull S, Heimgartner R, Hübers A, Jung HH, Kessler C, Knöpfel R, Laptseva N, Magini G, Manka R, Mazzucchelli L, Meyer M, Mihaylova V, Monney P, Mylonas A, Nkoulou R, Pabst T, Pfister O, Rüfer A, Schmidt A, Seeger H, Stämpfli SF, Stimmann G, Suter T, Treglia G, Tzankov A, Vetter F, Zweier M, Flammer AJ, Gerber B. Management of transthyretin amyloidosis. *Swiss Med Wkly.* 2021
- 7) Bonfiglio F, Bruscazzin A, Guidetti F, Terzi di Bergamo L, Faderl MR, Spina V, **Condoluci A**, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Piroso MC, Cittone MG, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista MJ, Bastidas G, Bea S, Boldorini R, Broccoli A, Bühler MM, Canzonieri V, Cascione L, Ceriani L, Cogliatti SB, Corradini P, Derenzini E, Devizzi L, Dietrich S, Elia AR, Facchetti F, Gaidano G, Garcia JF, Gerber B, Ghia P, Gomes da Silva M, Gritti G, Guidetti A, Hitz F, Inghirami GG, Ladetto M, López-Guillermo A, Lucchini E, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia AA, Mollejo M, Montalban C, Novak U, Oscier DG, Passamonti F, Piazza FA, Pizzolitto S, Rambaldi A, Sabattini E, Salles GA, Santambrogio E, Scarfo L, Stathis A, Stussi G, Geyer JT, Tapia G, Tarella C, Thieblemont C, Tousseyn T, Tucci A, Vanini G, Visco C, Vitolo U, Walewska R, Zaja F, Zenz T, Zinzani PL, Khiabani H, Calcinotto A, Bertoni F, Bhagat G, Campo E, de Leval L, Dirnhofer S, Pileri SA, Piris MA, Traverse-Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F, Zucca E, Rossi D. Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. *Blood.* 2021
- 8) Bruscazzin A, Terzi di Bergamo L, Spina V, Hodgkinson B, Forestieri G, Bonfiglio F, **Condoluci A**, Wu W, Piroso MC, Faderl MR, Koch R, Schaffer M, Alvarez JD, Fournieu N, Gerber B, Stussi G, Zucca E, Balasubramanian S, Rossi D. Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab. *Blood Adv.* 2021
- 9) Morabito F, Tripepi G, Moia R, Recchia AG, Boggione P, Mauro FR, Bossio S, D'Arrigo G, Martino EA, Vigna E, Storino F, Fronza G, Di Raimondo F, Rossi D, **Condoluci A**, Colombo M, Fais F, Fabris S, Foa R, Cutrona G, Gentile M, Montserrat E, Gaidano G, Ferrarini M, Neri A. Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. *Front Oncol.* 2021
- 10) Cittone MG, Battegay R, **Condoluci A**, Terzi di Bergamo L, Fernandes E, Galfetti E, Nosedà R, Leuppi-Taegtmeyer A, Drexler B, Ceschi A, Tsakiris DA, Berger CT, Favre G, Martin T, Korte W, Graf L, Martinez M, Gerber B. The statistical risk of diagnosing coincidental acquired hemophilia A following anti-SARS-CoV-2 vaccination. *J Thromb Haemost.* 2021

- 11) Morabito F, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Bossio S, Varettoni M, Murru R, Chiarenza A, Visentin A, **Condoluci A**, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Recchia AG, Rossi FM, Zucchetto A, Al-Janazreh H, Martino EA, Vigna E, Tripepi G, D'Arrigo G, Galimberti S, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G, Cutrona G, Jaksic O, Olivieri J, Rossi D, Di Raimondo F, Cuneo A, Gaidano G, Polliack A, Trentin L, Foà R, Ferrarini M, Gattei V, Gentile M. TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. *Am J Hematol*. 2021.
- 12) Morabito F, Tripepi G, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Bossio S, Varettoni M, Murru R, Chiarenza A, Visentin A, **Condoluci A**, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Al-Janazreh H, Vigna E, Martino EA, Cassin R, D'Arrigo G, Galimberti S, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G, Monti P, Menichini P, Olivieri J, Cutrona G, Rossi D, Cuneo A, Di Raimondo F, Gaidano G, Polliack A, Trentin L, Foà R, Ferrarini M, Gattei V, Gentile M. Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine. Results of study on 486 cases outside clinical trials. *Am J Hematol*. 2021
- 13) **Condoluci A**, Alberio L, Gomez FJ, Studt JD, Orlando C, Jochmans K, Gerber B. Thrombotic storm under DOAC treatment in a patient with homozygous antithrombin Budapest III mutation. *Thromb Res*. 2021
- 14) Morabito F, Tripepi G, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Varettoni M, Murru R, Chiarenza A, Visentin A, **Condoluci A**, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Vigna E, Martino EA, Mendicino F, Botta C, Caracciolo D, Cassin R, D'Arrigo G, Galimberti S, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G, Cutrona G, Rossi D, Di Raimondo F, Cuneo A, Gaidano G, Polliack A, Trentin L, Foà R, Ferrarini M, Gattei V, Gentile M. Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. *Am J Hematol*. 2021
- 15) **Condoluci A**, Rossi D. Richter syndrome. *Curr Oncol Rep*. 2021
- 16) Baumann T, Moia R, Gaidano G, Delgado J, **Condoluci A**, Villamor N, Payedimarri AB, Costa D, Patriarca A, Jiménez-Vicente C, Rossi D, Montserrat E. Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients. *Leukemia*. 2021
- 17) Gentile M, Morabito F, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Recchia AG, Varettoni M, Murru R, Chiarenza A, **Condoluci A**, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Fraticelli V, Vigna E, Botta C, Tripepi G, Arrigo G, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Rigolin GM, Rossi D, Di Raimondo F, Gaidano G, Polliack A, Cuneo A, Foà R, Gattei V. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. *Leukemia*. 2021
- 18) **Condoluci A**, Rossi D. Genomic Instability and Clonal Evolution in Chronic Lymphocytic Leukemia: Clinical Relevance. *J Natl Compr Canc Netw*. 2020
- 19) Morabito F, Tripepi G, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Bossio S, Varettoni M, Murru R, Chiarenza A, Visentin A, **Condoluci A**, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Al-Janazreh H, Vigna E, Martino EA, Mendicino F, Cassin R, D'Arrigo G, Galimberti S, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G, Monti P, Menichini P, Cutrona G, Jaksic O, Rossi D, Di Raimondo F, Cuneo A, Gaidano G, Polliack A, Trentin L, Foà R, Ferrarini M, Gattei V, Gentile M. Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. *Eur J Haematol*. 2020
- 20) Schwotzer R, Flammer AJ, Gerull S, Pabst T, Arosio P, Averaimo M, Bacher VU, Bode P, Cavalli A, **Condoluci A**, Dirnhofer S, Djerbi N, Dobner SW, Fehr T, Garofalo M, Gaspert A, Heimgartner R, Hübers A, Jung HH, Kessler C, Knöpfel R, Laptseva N, Manka R, Mazzucchelli L, Meyer M, Mihaylova V, Monney P, Mylonas A, Nkoulou R, Pazhenkottil A, Pfister O, Rüfer A, Schmidt A, Seeger H, Stämpfli SF, Stimimann G, Suter T, Théaudin M, Treglia G, Tzankov A, Vetter F, Zweier M, Gerber B. Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis. *Swiss Med Wkly*. 2020
- 21) **Condoluci A**, Rossi D. SOHO State of the Art Updates and Next Questions: Clonal Evolution in Chronic Lymphocytic Leukemia. *Clin Lymphoma Myeloma Leuk*. 2020
- 22) Rossi D, Shadman M, **Condoluci A**, Brown JR, Byrd JC, Gaidano G, Hallek M, Hillmen P, Mato A, Montserrat E, Ghia P. How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic. *HemaSphere*. 2020
- 23) **Condoluci A**, Terzi di Bergamo L, Langerbeins P, Hoehstetter MA, Herling CD, De Paoli L, Delgado J, Rabe KG, Gentile M, Doubek M, Mauro FR, Chiodin G, Mattsson M, Bahlo J, Cutrona G, Kotaskova J, Deambrogi C, Ekström Smedby K, Spina V, Bruscazzin A, Wu W, Moia R, Bianchi E, Gerber B, Zucca E, Gillessen S, Ghielmini ME, Cavalli F, Stuessi G, Hess MA, Baumann TS, Neri A, Ferrarini M, Rosenquist R, Forconi F, Foa R, Pospisilova S, Morabito F, Stilgenbauer S, Döhner H, Parikh SA, Wierda WG, Montserrat E, Gaidano G, Hallek M, Rossi D. International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia. *Blood*. 2020
- 24) **Condoluci A**, Rossi D. The future of cell-free DNA testing to guide therapeutic decisions in B-cell lymphomas. *Curr Opin Hematol*. 2019
- 25) **Condoluci A**, Rossi D. Genetic mutations in chronic lymphocytic leukemia: impact on clinical treatment. *Expert Rev Hematol*. 2019
- 26) Rossi D, **Condoluci A**, Spina V, Gaidano G. Methods for Measuring ctDNA in Lymphomas. *Methods Mol Biol*. 2019
- 27) **Condoluci A**, Rossi D, Zucca E, Cavalli F. Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma. *Curr Oncol Rep*. 2018
- 28) **Condoluci A**, Rossi D. Age-related clonal hematopoiesis and monoclonal B-cell lymphocytosis/chronic lymphocytic leukemia: a new association? *Haematologica*. 2018
- 29) Spina V, Bruscazzin A, Cuccaro A, Martini M, Di Trani M, Forestieri G, Manzoni M, **Condoluci A**, Arribas A, Terzi-Di-

Bergamo L, Locatelli SL, Cupelli E, Ceriani L, Moccia AA, Stathis A, Nassi L, Deambrogi C, Diop F, Guidetti F, Cocomazzi A, Annunziata S, Rufini V, Giordano A, Neri A, Boldorini R, Gerber B, Bertoni F, Ghielmini M, Stüssi G, Santoro A, Cavalli F, Zucca E, Larocca LM, Gaidano G, Hohaus S, Carlo-Stella C, Rossi D. Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma. *Blood*. 2018

- 30) **Condoluci A**, Rossi D. Treatment of Richter's Syndrome. *Curr Treat Options Oncol*. 2017
- 31) Rossi D, **Condoluci A**. Lenalidomide maintenance in high risk chronic lymphocytic leukaemia: practice changing study or hypothesis generating approach? *Lancet Haematol*. 2017
- 32) Bulian P, Bomben R, Bo MD, Zucchetto A, Rossi FM, Degan M, Pozzo F, Bittolo T, Bravin V, D'Agaro T, Cerri M, Chiarenza A, Chaffee KG, **Condoluci A**, D'Arena G, Spina M, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Poeta GD, Gaidano G, Shanafelt TD, Gattei V. Mutational status of *IGHV* is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. *Haematologica*. 2017
- 33) **Condoluci A**, Mazzara C, Zoccoli A, Pezzuto A, Tonini G. Impact of smoking on lung cancer treatment effectiveness: a review. *Future Oncol*. 2016
- 34) Crucitti P, Mangiameli G, Petitti T, **Condoluci A**, Rocco R, Gallo IF, Longo F, Rocco G. Does prophylactic ligation of the thoracic duct reduce chylothorax rates in patients undergoing oesophagectomy? A systematic review and meta-analysis. *Eur J Cardiothorac Surg*. 2016
- 35) **Condoluci A**, Leuzzi G, Inderbitzi R, Cafarotti S. eComment. Radical vs selective lymphadenectomy for non-small-cell lung cancer: which is the optimal procedure? *Interact Cardiovasc Thorac Surg*. 2015

Research grants and Awards

"Fondation pour la Recherche en Hématologie Peter Anton et Anna Katharina Miescher" & Swiss Society of Hematology 2022-2023 Research Prize : 100000 CHF. Project: Tumor microenvironment of high-risk follicular lymphoma.

IOSI START-UP program 2021: 40000 CHF. Project: Reprogramming the splenic marginal zone lymphoma-educated microenvironment to RESTORE immune surveillance.

Hematology Research Physician-Scientist Fellowship Award 2021 (Jacques & Gloria Gossweiler Foundation): 50000 CHF. Project: Reprogramming the splenic marginal zone lymphoma-educated microenvironment to RESTORE immune surveillance.

Gilead Swiss Fellowship Program, 2021: 50000 CHF. Project: Reprogramming the splenic marginal zone lymphoma-educated microenvironment to RESTORE immune surveillance

ASH Global Research Award, 2021: 150000 USD. Project: Evidence based monitoring of lymphoma by using of state-of-the-art circulating tumor DNA assay – A phase II diagnostic study.

Area Formazione, Ricerca e Innovazione (AFRI) Ente Ospedaliero Cantonale, 2020: 100000 CHF. Project: Reprogramming the splenic marginal zone lymphoma-educated microenvironment to RESTORE immune surveillance.

Project: Prevalence of amyloidosis in patients with lumbar spinal stenosis or carpal tunnel syndrome. Unrestricted grant from Pfizer, 2019: 30000 CHF.

Advisory Board for Research Ente Ospedaliero Cantonale (ABREOC) 2018: 30000 CHF. Project: International Prognostic Score for Early Stage CLL.

Reviewer Activity

Blood, Blood Advances, Annals of Hematology, Clinical Cancer Research, Hematological Oncology, Review Committee ICML (International Conference of Malignant Lymphoma)

Memberships

Swiss Hematologists and Oncologists of Tomorrow (SHOOT), Board Committee

Swiss Society of Hematology (SSH)

Swiss Medical Association (FMH)

European Hematology Association (EHA)

American Society of Hematology (ASH)

INSTITUTIONAL RESPONSIBILITIES

- | | |
|-------------------|--|
| 03/2022 – Present | Co-referent for the Onco-hematologic multi-disciplinary board
EOC - ORBV, Bellinzona (Switzerland) – Oncology Institute of Southern Switzerland |
| 08/2021 – Present | Referent for the Hematology monthly lectures
EOC - ORBV, Bellinzona (Switzerland) – Oncology Institute of Southern Switzerland |
-